On this page
Key takeaways
• Fisetin is a senolytic — it clears senescent cells. Urolithin A is a mitophagy inducer — it helps healthy cells recycle damaged mitochondria (1,2).
• Urolithin A has two published RCTs demonstrating muscle strength and endurance improvements in middle-aged and older adults (3,4). Fisetin’s equivalent RCT (AFFIRM) is unreported (8).
• Urolithin A is produced by gut bacteria from ellagitannins in pomegranate, walnuts, and berries. Only 30–40% of people produce meaningful amounts endogenously (7).
• Fisetin is directly bioavailable from strawberries (though at low levels) and from supplement capsules; urolithin A requires either specific gut microbiota or direct supplementation.
• The mechanisms are complementary — senolytic clearance for accumulated cellular dysfunction, mitophagy for ongoing mitochondrial maintenance.
• Urolithin A currently has the stronger human evidence base for muscle-function endpoints; fisetin has stronger preclinical senolytic activity.
Quick answer
Fisetin and urolithin A target different aspects of cellular ageing. Fisetin is a senolytic, clearing senescent cells that accumulate in tissue. Urolithin A is a mitophagy inducer, supporting the intracellular recycling of damaged mitochondria. Urolithin A currently has the stronger published human RCT evidence — two randomised trials in middle-aged and older adults have shown improvements in muscle strength, endurance, and mitochondrial biomarkers (3,4). Fisetin’s equivalent human trials are running but not yet reported. Combining the two is mechanistically coherent and common in longevity practice; if you must choose one, urolithin A has the stronger evidence for musculoskeletal endpoints today. For the full fisetin context, see our complete clinician’s guide.
Different targets, different mechanisms
Fisetin — clearing senescent cells
Fisetin’s senolytic mechanism removes senescent cells from tissue. This is a subtractive intervention aimed at reducing the accumulated pro-inflammatory signal from cells that have stopped dividing but continue secreting SASP factors. Fisetin has documented senolytic activity in mouse and human tissue explants (1) and produces effects on aged mouse muscle function equivalent to genetic clearance of p16-positive cells (6). The human clinical validation of this mechanism (AFFIRM, PROFFi, Fisetin HIGH) is pending.
Urolithin A — recycling damaged mitochondria
Urolithin A’s primary mechanism is induction of mitophagy — the selective autophagic clearance of damaged mitochondria. Ryu and colleagues (Nat Med, 2016) established this mechanism in preclinical work and demonstrated lifespan extension in C. elegans and improved muscle function in aged rodents (5). In humans, Andreux and colleagues (Nat Metab, 2019) reported that supplemental urolithin A improved biomarkers of mitochondrial health in healthy older adults (2). Two subsequent RCTs demonstrated functional muscle improvements (3,4).
Why the mechanisms are complementary
Senolytic clearance addresses damage that has already been done — the senescent cells accumulated over decades. Mitophagy induction addresses ongoing intracellular maintenance — the daily production and clearance of damaged mitochondria in healthy cells. Neither is a substitute for the other. A biology-informed longevity stack might reasonably include both.
Human clinical evidence — urolithin A’s current lead
Urolithin A has a more mature clinical trial base than fisetin. Three trials in particular anchor its evidence.
Andreux 2019 — the safety and biomarker trial
The first-in-human urolithin A trial randomised 60 healthy older adults to placebo, 250 mg, 500 mg, or 1,000 mg urolithin A for four weeks (2). The trial demonstrated safety across all doses and reported improvements in plasma acylcarnitines and other mitochondrial biomarkers at higher doses — consistent with the induction of mitophagy predicted from preclinical work.
Singh 2022 — the middle-aged muscle trial
Singh and colleagues (Cell Rep Med, 2022) randomised 88 sedentary middle-aged adults to urolithin A (500 mg or 1,000 mg) or placebo for four months (3). Both urolithin A doses improved leg muscle strength and exercise performance versus placebo. The 1,000 mg dose additionally improved biomarkers of mitochondrial function. This is the first Phase 2–level evidence for urolithin A improving a functional clinical endpoint in humans.
Liu 2022 — the older-adult muscle endurance trial
Liu and colleagues (JAMA Netw Open, 2022) randomised 66 older adults (>65 years) to 1,000 mg urolithin A or placebo for four months and reported improved muscle endurance and mitochondrial biomarkers in the intervention arm (4). This trial explicitly targeted the older-adult population most likely to benefit from mitochondrial support.
Fisetin’s human evidence
Fisetin has no equivalent published RCT for a functional endpoint. AFFIRM (NCT03430037) tests the pulsed protocol against frailty; results are unreported since 2018. PROFFi and Fisetin HIGH are in earlier stages (8). When AFFIRM publishes, the comparison will change. Until then, urolithin A has a clearer human clinical case.
The gut microbiota question
A distinctive feature of urolithin A is that it is produced by gut bacteria from ellagitannins in pomegranate, walnuts, and berries. Not everyone produces meaningful amounts endogenously — only approximately 30 to 40 percent of people are urolithin A "producers" (7). Non-producers can achieve the biological effect only via supplemental urolithin A. This is one of the strongest arguments for supplementation of urolithin A rather than reliance on dietary sources: for the majority of the population, dietary ellagitannin intake does not produce meaningful urolithin A levels.
Fisetin has no equivalent bacterial-conversion step. It is directly present in strawberries and other fruits and does not require gut microbiota to be biologically active. Dietary intake is universally accessible, though quantitatively small compared to supplemental doses. See our foods high in fisetin article.
Dosing and bioavailability comparison
|
Aspect |
Fisetin |
Urolithin A |
|
Mechanism |
Senolytic (clears senescent cells) |
Mitophagy inducer (recycles damaged mitochondria) |
|
Typical dose |
100–500 mg daily or 20 mg/kg pulsed |
500–1,000 mg daily continuous |
|
Bioavailability |
Poor (unformulated); improved with hydrogel/liposomal |
Moderate; direct oral absorption |
|
Human RCT with clinical endpoint |
None yet published |
|
|
Requires gut microbiota |
No |
Yes (or direct supplement) |
|
Cost per month |
Modest |
Higher (patented compound) |
When to choose which
For muscle function specifically, urolithin A has the stronger current human evidence — two RCTs showing muscle strength or endurance improvement (3,4). If frailty prevention or muscle preservation is your primary endpoint, this is where the evidence points today. Our fisetin for muscle and frailty article covers the fisetin muscle case.
For senescent cell clearance specifically, fisetin is the more mechanistically direct choice. Urolithin A does not primarily clear senescent cells; it improves the health of existing cells.
For broader anti-inflammatory and cardiovascular support, both compounds have preclinical activity but neither has strong specific human evidence.
For cost-conscious supplementation, fisetin capsules are typically less expensive per month than urolithin A. Urolithin A is a newer patented commercial supplement with a smaller number of suppliers.
The stacking case
Combining fisetin and urolithin A is mechanistically coherent. Both address different but complementary aspects of cellular ageing. Neither competes with the other for absorption pathways. No known negative interaction. Both benefit from co-ingestion with a fatty meal (fisetin more than urolithin A). Practical stacking: urolithin A at 500 mg daily with breakfast (continuous); fisetin at the pulsed 20 mg/kg dose on two days per month, or at continuous 250–500 mg daily. See our how and when to take fisetin article.
What we still don't know
• Whether fisetin plus urolithin A produces additive human clinical effects. Not tested.
• Whether fisetin’s AFFIRM outcome, when it publishes, will match urolithin A’s muscle-function results. This will directly change the current comparison.
• Whether urolithin A has senolytic activity at higher doses that could partially overlap with fisetin’s mechanism. Preclinical hints exist but are not well characterised in humans.
• How the two compounds interact with concurrent exercise training. Both may enhance exercise-induced adaptation; the specific dose-response has not been characterised.
Bottom line
Urolithin A currently has the stronger human RCT evidence, particularly for muscle function endpoints in middle-aged and older adults (3,4). Fisetin has the stronger preclinical senolytic biology and stronger mechanistic case for clearing accumulated senescent cells, but the human clinical validation is pending. The mechanisms are complementary and combining them is defensible. If muscle preservation is your priority endpoint, urolithin A is the stronger evidence-based choice today. If you want to bet on the senolytic hypothesis specifically, fisetin is the more direct choice. Taking both is mechanistically coherent. When AFFIRM publishes, this comparison will be revisited. For the full context, see our complete clinician’s guide and dedicated senolytic article.
Frequently asked questions
Is urolithin A better than fisetin?
For muscle function endpoints today, urolithin A has the stronger human evidence (3,4). For senolytic-mechanism specifically, fisetin is the more direct choice.
Can I take both fisetin and urolithin A?
Yes. Different mechanisms, no known interaction. Take together with breakfast.
Is urolithin A more bioavailable than fisetin?
Yes, generally. Urolithin A has better direct oral absorption than unformulated fisetin — one of the reasons its human trials have shown clearer functional effects.
Do I need urolithin A if I eat pomegranates?
Only if you are a urolithin A producer — about 30–40% of people (7). Non-producers get little urolithin A benefit from dietary ellagitannins. Direct supplementation is the reliable route.
Which is safer?
Both have favourable safety profiles at supplemental doses across the completed trials (2,3,4). Neither has documented serious adverse events.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1(6):595-603. https://pubmed.ncbi.nlm.nih.gov/32694802/
3. Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022;3(5):100633. https://pubmed.ncbi.nlm.nih.gov/35584623/
4. Liu S, D’Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2144279. https://pubmed.ncbi.nlm.nih.gov/35050355/
5. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016;22(8):879-888. https://pubmed.ncbi.nlm.nih.gov/27400265/
6. Murray KO, Mahoney SA, Venturini S, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging. Aging Cell. 2025;24:e70114. https://doi.org/10.1111/acel.70114
7. Cortés-Martín A, Selma MV, Tomás-Barberán FA, González-Sarrías A, Espín JC. Where to find a good urolithin producer: gut microbiota metabotypes. Trends Food Sci Technol. 2020;99:56-72. https://www.sciencedirect.com/science/article/abs/pii/S0924224419309847
8. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037